348 related articles for article (PubMed ID: 21838035)
1. [Anti-tuberculosis chemotherapy and management of adverse reactions].
Kuwabara K
Nihon Rinsho; 2011 Aug; 69(8):1389-93. PubMed ID: 21838035
[TBL] [Abstract][Full Text] [Related]
2. [Short-course chemotherapy of tuberculosis with pyrazinamide].
Asai S; Futsuki Y; Tomari S; Araki J
Nihon Rinsho; 1998 Dec; 56(12):3087-90. PubMed ID: 9883615
[TBL] [Abstract][Full Text] [Related]
3. [Characteristics and treatment outcomes of INH-resistant or RFP-resistant tuberculosis].
Saito W; Nagayama N; Miyamoto M; Hara H; Suzuki J; Masuda K; Baba M; Tamura A; Nagai H; Akagawa S; Kawabe Y; Machida K; Kurashima A; Yotsumoto H
Kekkaku; 2003 Oct; 78(10):611-7. PubMed ID: 14621568
[TBL] [Abstract][Full Text] [Related]
4. [Desensitization therapy for allergic reactions of antituberculous drugs--evaluation of desensitization therapy according to the guideline of the Japanese Society for Tuberculosis].
Kobashi Y; Okimoto N; Matsushima T; Abe T; Nishimura K; Shishido S; Kawahara S; Shigeto E; Takeyama H; Kuraoka T
Kekkaku; 2000 Dec; 75(12):699-704. PubMed ID: 11201137
[TBL] [Abstract][Full Text] [Related]
5. [Effectiveness and problems of PZA-containing 6-month regimen for the treatment of new pulmonary tuberculosis patients].
Wada M
Kekkaku; 2001 Jan; 76(1):33-43. PubMed ID: 11211781
[TBL] [Abstract][Full Text] [Related]
6. Intermittent tuberculosis treatment for patients with isoniazid intolerance or drug resistance.
Reves R; Heilig CM; Tapy JM; Bozeman L; Kyle RP; Hamilton CD; Bock N; Narita M; Wing D; Hershfield E; Goldberg SV;
Int J Tuberc Lung Dis; 2014 May; 18(5):571-80. PubMed ID: 24903795
[TBL] [Abstract][Full Text] [Related]
7. [Side effects of various combinations of rifampin and isoniazid with ethambutol or streptomycin and pyrazinamide in short-term chemotherapy of newly-detected pulmonary tuberculosis].
Zierski M; Bek E
Pneumonol Pol; 1980 Jul; 48(7):469-79. PubMed ID: 7433146
[No Abstract] [Full Text] [Related]
8. [Drug-induced hepatotoxicity caused by anti-tuberculosis drugs in tuberculosis patients complicated with chronic hepatitis].
Kaneko Y; Nagayama N; Kawabe Y; Shimada M; Suzuki J; Kunogi M; Matsui Y; Kawashima M; Suzuki J; Ariga H; Oshima N; Masuda K; Matsui H; Nagai H; Tamura A; Akagawa S; Toyoda E; Machida K; Kurashima A; Yotsumoto H
Kekkaku; 2008 Jan; 83(1):13-9. PubMed ID: 18283910
[TBL] [Abstract][Full Text] [Related]
9. [Agranulocytosis due to anti-tuberculosis drugs including isoniazid (INH) and rifampicin (RFP)--a report of four cases and review of the literature].
Shishido Y; Nagayama N; Masuda K; Baba M; Tamura A; Nagai H; Akagawa S; Kawabe Y; Machida K; Kurashima A; Komatsu H; Yotsumoto H
Kekkaku; 2003 Nov; 78(11):683-9. PubMed ID: 14672045
[TBL] [Abstract][Full Text] [Related]
10. [Anti-tuberculosis chemotherapy].
Wada M
Kekkaku; 2007 Oct; 82(10):771-81. PubMed ID: 18018601
[TBL] [Abstract][Full Text] [Related]
11. Treatment of lymph node tuberculosis--a randomized clinical trial of two 6-month regimens.
Jawahar MS; Rajaram K; Sivasubramanian S; Paramasivan CN; Chandrasekar K; Kamaludeen MN; Thirithuvathas AJ; Ananthalakshmi V; Prabhakar R
Trop Med Int Health; 2005 Nov; 10(11):1090-8. PubMed ID: 16262733
[TBL] [Abstract][Full Text] [Related]
12. [Six-month short course chemotherapy containing pyrazinamide for initial treatment of pulmonary tuberculosis].
Wada M; Yosiyama T; Yosikawa M; Ogata H; Sugie T; Nakasono T; Sugita H
Kekkaku; 1994 Nov; 69(11):671-80. PubMed ID: 7837720
[TBL] [Abstract][Full Text] [Related]
13. Fixed-dose combination chemotherapy (Rifater/Rifinah) for active pulmonary tuberculosis in Taiwan: a two-year follow-up.
Su WJ; Perng RP
Int J Tuberc Lung Dis; 2002 Nov; 6(11):1029-32. PubMed ID: 12475151
[TBL] [Abstract][Full Text] [Related]
14. [Controlled trial of isoniazid.rifampicin.ethambutol regimen and isoniazid.rifampicin.pyrazinamide regimen in the primary chemotherapy for pulmonary tuberculosis (author's transl)].
Kekkaku; 1980 Jan; 55(1):7-13. PubMed ID: 6988627
[No Abstract] [Full Text] [Related]
15. Short-course tuberculosis chemotherapy studies conducted in Poland during the past decade.
Snider DE; Zierski M; Graczyk J; Bek E; Farer LS
Eur J Respir Dis; 1986 Jan; 68(1):12-8. PubMed ID: 3512281
[TBL] [Abstract][Full Text] [Related]
16. Adverse drug reactions observed during DOTS.
Dhingra VK; Rajpal S; Aggarwal N; Aggarwaln JK; Shadab K; Jain SK
J Commun Dis; 2004 Dec; 36(4):251-9. PubMed ID: 16506547
[TBL] [Abstract][Full Text] [Related]
17. Four-month, four-drug preventive therapy for inactive pulmonary tuberculosis.
Goldberg SV; Duchin JS; Shields T; Nolan CM
Am J Respir Crit Care Med; 1999 Aug; 160(2):508-12. PubMed ID: 10430721
[TBL] [Abstract][Full Text] [Related]
18. [Desensitization therapy for antituberculous drugs].
Kobashi Y; Okimoto N; Matsushima T; Abe T; Nishimura K; Shishido S; Kawahara S; Shigeto E; Takeyama H; Kuraoka T
Kekkaku; 2000 Sep; 75(9):521-6. PubMed ID: 11068368
[TBL] [Abstract][Full Text] [Related]
19. [Evaluation of the streptomycin twice weekly with INH and RFP for initial therapy of pulmonary tuberculosis].
Toyota E; Suzuki T; Tagawa K; Takahara M; Ito M; Arai T; Kabe J; Baba H
Kekkaku; 1994 Sep; 69(9):559-63. PubMed ID: 7967317
[TBL] [Abstract][Full Text] [Related]
20. Assessment of a combined preparation of isoniazid, rifampicin and pyrazinamide (Rifater) in the initial phase of chemotherapy in three 6-month regimens for smear-positive pulmonary tuberculosis: a five-year follow-up report.
Teo SK
Int J Tuberc Lung Dis; 1999 Feb; 3(2):126-32. PubMed ID: 10091877
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
